{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:48:47Z","timestamp":1785919727672,"version":"3.56.0"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple myeloma (MM) is a hematologic malignancy driven by clonal plasma-cell proliferation and remains largely incurable owing to disease relapse and acquired drug resistance. Ferroptosis, an iron-dependent form of regulated cell death characterized by excessive lipid peroxidation, has emerged as a potential therapeutic target in cancer and is increasingly implicated in MM biology. Unlike apoptosis and other classical cell death pathways, ferroptosis is closely associated with dysregulated iron metabolism, oxidative stress, and lipid peroxidation, all of which are key features of MM biology. This review first outlines the molecular mechanisms of ferroptosis and then summarizes current evidence linking ferroptosis to MM progression, therapeutic resistance, and emerging therapeutic strategies. In addition, current therapeutic strategies targeting ferroptosis are discussed, including inhibition of system Xc\u2212, direct targeting of GPX4, modulation of iron metabolism, and their potential synergistic effects with existing anti-myeloma therapies. Finally, the major challenges associated with clinical translation are highlighted, together with future directions for biomarker development and ferroptosis-based therapeutic strategies. Collectively, ferroptosis represents a promising therapeutic concept for exploiting redox and metabolic vulnerabilities in MM. Nevertheless, current knowledge is derived predominantly from preclinical studies, and successful clinical translation will require improved tumor selectivity, rigorous safety evaluation, and biomarker-guided patient stratification.<\/jats:p>","DOI":"10.3389\/fonc.2026.1897942","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:14:01Z","timestamp":1785917641000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ferroptosis in multiple myeloma: molecular mechanisms and therapeutic opportunities"],"prefix":"10.3389","volume":"16","author":[{"given":"Wanfu","family":"Jiang","sequence":"first","affiliation":[{"name":"School of Medicine, Anhui University of Science and Technology","place":["Huainan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Anhui No. 2 Provincial People\u2019s Hospital (Affiliated Hospital of Anhui Second Medical College)","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changling","family":"Zhu","sequence":"additional","affiliation":[{"name":"Graduate School, Bengbu Medical University","place":["Bengbu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangqiang","family":"Bai","sequence":"additional","affiliation":[{"name":"School of Medicine, Anhui University of Science and Technology","place":["Huainan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihao","family":"Peng","sequence":"additional","affiliation":[{"name":"The First Hospital of Anhui University of Science and Technology","place":["Huainan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiology, Anhui No. 2 Provincial People\u2019s Hospital (Affiliated Hospital of Anhui Second Medical College)","place":["Hefei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/157496","article-title":"Bone marrow microenvironment in multiple myeloma progression","volume":"2012","author":"Manier","year":"2012","journal-title":"J BioMed Biotechnol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.139","article-title":"The role of LNK\/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders","volume":"31","author":"Maslah","year":"2017","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27073001","article-title":"Oxidative stress in multiple myeloma: pathogenic mechanisms, biomarkers, and redox-targeted therapeutic strategies","volume":"27","author":"Bilski","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12094-021-02669-8","article-title":"Ferroptosis: an iron-dependent cell death form linking metabolism, diseases, immune cell and targeted therapy","volume":"24","author":"Li","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1269451","article-title":"Mechanisms and regulations of ferroptosis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12935-026-04276-5","article-title":"Ferroptosis targeting: a novel therapeutic armamentarium in multiple myeloma","volume":"26","author":"Wang","year":"2026","journal-title":"Cancer Cell Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood.2025029950","article-title":"Targeting STK17B kinase activates ferroptosis and suppresses drug resistance in multiple myeloma","volume":"147","author":"Yan","year":"2026","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-026-01128-z","article-title":"Translating ferroptosis into oncology: challenges, opportunities and future directions","volume":"23","author":"Kang","year":"2026","journal-title":"Nat Rev Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.01.013","article-title":"Immunogenicity of ferroptosis in cancer: a matter of context","volume":"10","author":"Catanzaro","year":"2024","journal-title":"Trends Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1538615","article-title":"Discovery platform for inhibitors of IgH gene enhancer activity","volume":"20","author":"Dolloff","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.clml.2019.09.121","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.70215","article-title":"Whole genome and single-cell RNA sequencing reveals clonal evolution and heterogeneity of secondary plasma cell leukemia: a case report","volume":"7","author":"Suzuki","year":"2026","journal-title":"EJHaem"},{"key":"B16","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1182\/blood-2018-99-117577","article-title":"Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma, thereby promoting plasma cell survival and proteasome inhibitor resistance","volume":"132","author":"Shirazi","year":"2018","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.12","article-title":"Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker","volume":"7","author":"Chavan","year":"2017","journal-title":"Blood Cancer J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/s41467-024-45561-z","article-title":"Epigenetic regulation of CD38\/CD48 by KDM6A mediates NK cell response in multiple myeloma","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple myeloma: signaling pathways and targeted therapy","volume":"5","author":"Lu","year":"2024","journal-title":"Mol BioMed"},{"key":"B21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/sj.leu.2403560","article-title":"Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support","volume":"19","author":"Bertrand","year":"2005","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2048-5","article-title":"Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma","volume":"104","author":"Furukawa","year":"2016","journal-title":"Int J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2020.1810918","article-title":"Ferroptosis: machinery and regulation","volume":"17","author":"Chen","year":"2021","journal-title":"Autophagy"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1102471","article-title":"The immune suppressive tumor microenvironment in multiple myeloma: the contribution of myeloid-derived suppressor cells","volume":"13","author":"Giannotta","year":"2022","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1346211","article-title":"Different evasion strategies in multiple myeloma","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10173","article-title":"Multiple myeloma and fatty acid metabolism","volume":"3","author":"Masarwi","year":"2019","journal-title":"JBMR Plus"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/biom16050710","article-title":"Microenvironmental drivers of bone disease in multiple myeloma: oxidative stress, sterile inflammation, autophagy-lysosomal remodeling, and the iron-lipid peroxidation axis","volume":"16","author":"Nasso","year":"2026","journal-title":"Biomolecules"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-269126","article-title":"Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug","volume":"116","author":"Hu","year":"2010","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00462-0","article-title":"Broadening horizons: the role of ferroptosis in cancer","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.122","article-title":"The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma","volume":"25","author":"Martin","year":"2011","journal-title":"Leukemia"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210518","article-title":"Ferroptosis in infection, inflammation, and immunity","volume":"218","author":"Chen","year":"2021","journal-title":"J Exp Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","article-title":"Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2026.103523","article-title":"Targeting GPX4 in neurodegenerative disorder: unlocking ferroptosis as a therapeutic frontier","volume":"101","author":"Kumar","year":"2026","journal-title":"Tissue Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.07.043","article-title":"NCOA4-mediated ferritinophagy induces ferroptosis and enriches ferritin-containing EVs via ferritin phase separation to promote mechanical ventilation-induced pulmonary fibrosis","volume":"82","author":"Huang","year":"2026","journal-title":"J Adv Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2016.1187366","article-title":"Autophagy promotes ferroptosis by degradation of ferritin","volume":"12","author":"Hou","year":"2016","journal-title":"Autophagy"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05762-4","article-title":"Bortezomib elevates intracellular free Fe(2+) by enhancing NCOA4-mediated ferritinophagy and synergizes with RSL-3 to inhibit multiple myeloma cells","volume":"103","author":"Zhang","year":"2024","journal-title":"Ann Hematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1606804","article-title":"Ferroptosis: a novel pharmacological mechanism against multiple myeloma","volume":"16","author":"Shi","year":"2025","journal-title":"Front Pharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2239","article-title":"ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition","volume":"13","author":"Doll","year":"2017","journal-title":"Nat Chem Biol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-1-0716-3433-2_6","article-title":"Probing lipid peroxidation in ferroptosis: emphasizing the utilization of C11-BODIPY-based protocols","volume":"2712","author":"Dai","year":"2023","journal-title":"Methods Mol Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2026.01.008","article-title":"Decoding GPX4 regulation in ferroptosis: mechanisms and therapeutic implications","author":"Chen","year":"2026","journal-title":"Trends Mol Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2025.09.003","article-title":"Regulating SLC7A11\/GSH\/GPX4 axis by glucose dyshomeostasis to simultaneously promote disulfidptosis, cuproptosis and ferroptosis","volume":"54","author":"Zhang","year":"2025","journal-title":"Bioact Mater"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw2238","article-title":"Clockophagy is a novel selective autophagy process favoring ferroptosis","volume":"5","author":"Yang","year":"2019","journal-title":"Sci Adv"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142625","article-title":"Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins","volume":"136","author":"Panaroni","year":"2020","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104906","article-title":"Cysteine metabolism at the crossroads of ferroptosis and cancer therapy","volume":"215","author":"Lee","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32080456","article-title":"Roles and prospective applications of ferroptosis suppressor protein 1 (FSP1) in Malignant tumor treatment","volume":"32","author":"Jin","year":"2025","journal-title":"Curr Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cells14231889","article-title":"Dihydroorotate dehydrogenase in mitochondrial ferroptosis and cancer therapy","volume":"14","author":"Lee","year":"2025","journal-title":"Cells"},{"key":"B49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1021\/acscentsci.9b01063","article-title":"GTP cyclohydrolase 1\/tetrahydrobiopterin counteract ferroptosis through lipid remodeling","volume":"6","author":"Kraft","year":"2020","journal-title":"ACS Cent Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70566","article-title":"The role of P62\/Nrf2\/Keap1 signaling pathway in lead-induced neurological dysfunction","volume":"31","author":"Peng","year":"2025","journal-title":"CNS Neurosci Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01250-z","article-title":"Research progress on ferroptosis in multiple myeloma","volume":"25","author":"Li","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"B52","first-page":"498","article-title":"Iron oxide nanoparticles inhibit tumor growth by ferroptosis in diffuse large B-cell lymphoma","volume":"13","author":"Huang","year":"2023","journal-title":"Am J Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.999688","article-title":"A novel ferroptosis-related gene signature for predicting prognosis in multiple myeloma","volume":"13","author":"Gao","year":"2023","journal-title":"Front Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-023-01909-2","article-title":"Multiple myeloma with high expression of SLC7A11 is sensitive to erastin-induced ferroptosis","volume":"29","author":"Zhang","year":"2024","journal-title":"Apoptosis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1203125","article-title":"Comprehensive analysis of ferroptosis-related genes in immune infiltration and prognosis in multiple myeloma","volume":"14","author":"Wang","year":"2023","journal-title":"Front Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s10238-025-01673-4","article-title":"DEK facilitates bortezomib resistance of multiple myeloma by modulating ferroptosis","volume":"25","author":"Wang","year":"2025","journal-title":"Clin Exp Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/ph18030325","article-title":"Therapeutic approaches with iron oxide nanoparticles to induce ferroptosis and overcome radioresistance in cancers","volume":"18","author":"Sant'Angelo","year":"2025","journal-title":"Pharm (Basel)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1186\/s40170-026-00428-3","article-title":"Tumor cell death by ferroptosis contributes to an immunosuppressive tumor microenvironment in syngeneic murine models of cancer","volume":"14","author":"Mbah","year":"2026","journal-title":"bioRxiv"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101436","article-title":"NFE2L1-mediated proteasome function protects from ferroptosis","volume":"57","author":"Kotschi","year":"2022","journal-title":"Mol Metab"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102411","article-title":"Targeting reactive oxygen species metabolism to induce myeloma cell death","volume":"13","author":"Caillot","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41420-022-01212-0","article-title":"GPX4-independent ferroptosis-a new strategy in disease's therapy","volume":"8","author":"Ma","year":"2022","journal-title":"Cell Death Discov"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.4206570","article-title":"Ferroptosis-modulating small molecules for targeting drug-resistant cancer: Challenges and opportunities in manipulating redox signaling","volume":"43","author":"Koeberle","year":"2023","journal-title":"Med Res Rev"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nature24297","article-title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","volume":"551","author":"Hangauer","year":"2017","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2023.05.003","article-title":"Regulation of ferroptosis by lipid metabolism","volume":"33","author":"Pope","year":"2023","journal-title":"Trends Cell Biol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1705-2","article-title":"The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis","volume":"575","author":"Bersuker","year":"2019","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.207704","article-title":"A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis","volume":"104","author":"Besse","year":"2019","journal-title":"Haematologica"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010335","article-title":"Class II ferroptosis inducers are a novel therapeutic approach for t (4;14)-positive multiple myeloma","volume":"8","author":"Zhang","year":"2024","journal-title":"Blood Adv"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1707-0","article-title":"FSP1 is a glutathione-independent ferroptosis suppressor","volume":"575","author":"Doll","year":"2019","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-6587955\/v1","article-title":"Novel (1S,3R)-RSL3-encapsulated polyunsaturated fatty acid rich liposomes sensitise multiple myeloma cells to ferroptosis-mediated cell death","volume":"26","author":"Habib","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B70","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41392-020-00216-5","article-title":"The interaction between ferroptosis and lipid metabolism in cancer","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduction Targeted Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00737-1","article-title":"Epigenetic and post-translational regulatory networks of ferroptosis in the tumor immune microenvironment","volume":"15","author":"Du","year":"2026","journal-title":"Exp Hematol Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.149257","article-title":"SLC7A11 as a molecular nexus of prognosis, resistance, and therapeutic roadmap in cancer: A systematic review and meta-analysis","volume":"335","author":"Sharma","year":"2026","journal-title":"Int J Biol Macromol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"Of1","DOI":"10.1158\/1535-7163.mct-25-0667","article-title":"Lipophilic statins deplete GPX4 to promote ferroptosis and sensitize cancer cells to immune checkpoint blockade","author":"Talty","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1177\/20406207261419810","article-title":"The role of antioxidants in multiple myeloma: diagnostic, prognostic, and therapeutic applications: a narrative review","volume":"17","author":"Admas","year":"2026","journal-title":"Ther Adv Hematol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.128","article-title":"Commentary on Perrone et\u00a0al.: 'vitamin C: not for breakfast anymore.if you have myeloma'","volume":"23","author":"Harvey","year":"2009","journal-title":"Leukemia"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2026.2636394","article-title":"PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators","volume":"41","author":"Periyasamy","year":"2026","journal-title":"J Enzyme Inhib Med Chem"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2016.08.124","article-title":"Identification of ACSL4 as a biomarker and contributor of ferroptosis","volume":"478","author":"Yuan","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"B78","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cell.2017.11.048","article-title":"Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis","volume":"172","author":"Ingold","year":"2018","journal-title":"Cell"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1519300","article-title":"Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects","volume":"16","author":"Horenstein","year":"2025","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00760","article-title":"CD38 in adenosinergic pathways and metabolic re-programming in human multiple myeloma cells: In-tandem insights from basic science to therapy","volume":"10","author":"Horenstein","year":"2019","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109235","article-title":"The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity","volume":"35","author":"Xu","year":"2021","journal-title":"Cell Rep"},{"key":"B83","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1182\/blood-2023-179444","article-title":"Ferroptosis inhibition generates TCF-1 + CAR-T cells with enhanced persistence and cytotoxicity","volume":"142","author":"Harada","year":"2023","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12967-026-07749-3","article-title":"Zalcitabine induces ferroptosis in multiple myeloma through the TFAM-cGAS-STING-SLC7A11 axis","volume":"24","author":"Hui","year":"2026","journal-title":"J Transl Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-026-42123-9","article-title":"IRX4204 sensitizes multiple myeloma to ferroptosis and improves lenalidomide efficacy through the HMOX1-GPX4 axis","volume":"16","author":"Wu","year":"2026","journal-title":"Sci Rep"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2023.109622","article-title":"Andrographolide induced ferroptosis in multiple myeloma cells by regulating the P38\/Nrf2\/HO-1 pathway","volume":"742","author":"Li","year":"2023","journal-title":"Arch Biochem Biophys"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155401","article-title":"Ethanol extract of Eclipta prostrata induces multiple myeloma ferroptosis via Keap1\/Nrf2\/HO-1 axis","volume":"128","author":"Li","year":"2024","journal-title":"Phytomedicine"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.021","article-title":"Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease","volume":"171","author":"Stockwell","year":"2017","journal-title":"Cell"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/nature05859","article-title":"RAS\u2013RAF\u2013MEK-dependent oxidative cell death involving voltage-dependent anion channels","volume":"447","author":"Yagoda","year":"2007","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03020-5","article-title":"Bone marrow stromal cells dictate lanosterol biosynthesis and ferroptosis of multiple myeloma","volume":"43","author":"Jiang","year":"2024","journal-title":"Oncogene"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1897942\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:14:03Z","timestamp":1785917643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1897942\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":90,"alternative-id":["10.3389\/fonc.2026.1897942"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1897942","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1897942"}}